苏茵解毒方治疗肾虚浊毒型3~5期慢性肾脏病的临床疗效及对血清Klotho的影响

Clinical Efficacy of Suyin Jiedu Prescription in the Treatment of Stage 3-5 Chronic Kidney Disease of Kidney Deficiency and Turbid Toxin Type and Its Effect on Serum Klotho

  • 摘要:
    目的 探索苏茵解毒方治疗肾虚浊毒型3~5期非透析慢性肾脏病的临床疗效及对血清Klotho、炎症水平的影响。
    方法 将符合纳入标准的102例肾虚浊毒型3~5期非透析慢性肾脏病患者随机分为治疗组、对照组各51例,共完成84例,其中对照组44例、治疗组40例。对照组予西医常规基础治疗,治疗组在对照组治疗基础上加服苏茵解毒方,2组疗程均为16周。治疗前后观察2组患者肾功能相关指标血红蛋白(Hb)、血清白蛋白(Alb)、尿素氮(BUN)、血肌酐(Scr)、估算肾小球滤过率(eGFR)、24 h尿蛋白定量(UTP)水平及中医证候积分变化,ELISA法检测血清Klotho、肿瘤坏死因子α(TNF-α)和白细胞介素18(IL-18)水平变化。治疗后比较2组临床疗效。
    结果 治疗后,2组患者BUN、Scr明显降低(P<0.05),eGFR显著增加(P<0.05,P<0.01),治疗组优于对照组(P<0.05);2组中医证候积分均显著降低(P<0.05,P<0.01),治疗组优于对照组(P<0.05,P<0.01);治疗组血清Klotho水平明显升高(P<0.05),IL-18水平显著降低(P<0.01),治疗组血清Klotho、TNF-α、IL-18水平均优于对照组(P<0.05,P<0.01)。治疗组临床总有效率高于对照组(P<0.01)。
    结论 苏茵解毒方能够有效改善肾虚浊毒型3~5期非透析慢性肾脏病患者肾功能,缓解临床症状,可能与提高Klotho水平、减轻体内炎症状态有关。

     

    Abstract:
    OBJECTIVE To explore the clinical efficacy of Suyin Jiedu Prescription in the treatment of Stage 3-5 non-dialysis chronic kidney disease of kidney deficiency and turbid toxin type and its effect on serum Klotho and inflammation levels.
    METHODS A total of 102 patients with Stage 3-5 non-dialysis chronic kidney disease of kidney deficiency and turbid toxin type who met the inclusion criteria were randomly divided into a treatment group and a control group, 51 cases in each group; a total of 84 cases were completed, including 44 cases in the control group and 40 cases in the treatment group. The control group was given conventional Western medicine basic treatment, and the treatment group was given Suyin Jiedu Prescription on the basis of the control group treatment. The treatment course of both groups was 16 weeks. The levels of renal function indexes hemoglobin (Hb), serum albumin (Alb), urea nitrogen (BUN), serum creatinine (Scr), estimated glomerular filtration rate (eGFR), 24 h urine protein (UTP) and TCM syndrome scores were observed in the two groups before and after treatment. The levels of serum Klotho, tumor necrosis factor α (TNF-α) and interleukin 18 (IL-18) were detected by ELISA. The clinical efficacy between the two groups after treatment was compared.
    RESULTS After treatment, BUN and Scr levels of the two groups of patients were significantly decreased (P < 0.05), eGFR was significantly increased (P < 0.05, P < 0.01), the treatment group was better than the control group (P < 0.05); the TCM syndrome scores of the two groups were significantly decreased (P < 0.05, P < 0.01), and the treatment group was better than the control group (P < 0.05, P < 0.01); the serum Klotho level in the treatment group was significantly increased (P < 0.05), the IL-18 level was significantly decreased (P < 0.01), and the serum Klotho, TNF-α, and IL-18 levels in the treatment group were better than those in the control group (P < 0.05, P < 0.01). The total clinical effective rate in the treatment group was higher than that in the control group (P < 0.01).
    CONCLUSION Suyin Jiedu Prescription can effectively improve renal function and relieve clinical symptoms in patients with Stage 3-5 non-dialysis chronic kidney disease of kidney deficiency and turbid toxin type, which may be related to increasing Klotho level and reducing inflammation in the body.

     

/

返回文章
返回